- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03568136
Investigation of Efficacy of Secukinumab in Patients With Moderate to Serve Atopic Dermatitis (Secu_in_AD)
A Randomized, Placebo-controlled, Double-blind Study to Scrutinize the Efficacy of Secukinumab in Patients With Moderate to Severe Atopic Dermatitis
Study Overview
Status
Intervention / Treatment
Detailed Description
Secukinumab is a humanized anti-IL-17A monoclonal antibody. Since Secukinumab is well established in the therapy of psoriasis with a highly favorable benefit to risk ration and IL-17 has been described in atopic dermatitis this study aims to investigate the effects of anti-IL-17 in atopic dermatitis.
This is a randomized, placebo-controlled, multicenter, double-blinded study to evaluate the efficacy and safety of subcutaneous Secukinumab compared to placebo in 45 adults with atopic dermatitis.
The study consists of 3 periods: a screening period of at least -14 days and up to -35 days, and a treatment period of 16 weeks and a follow-up period of additional 8 weeks. During the screening period eligibility of the patients is confirmed. Eligible patients are randomized 2:1 to treatment arm A or B at Day -7 (+2 to -15) during the randomization visit. Secukinumab (Cosentyx®) will be used according to the official label and SmPC (Summary of Product Characteristics). Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e. 2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16. For assessments of the study endpoints visits are performed at weeks 20 and 24. Placebo will be administered as 2 subcutaneous injections. Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16. For assessments of the study endpoints visits are performed at weeks 20 and 24.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
-
Dresden, Germany, 01069
- Klinische Forschung Dresden GmbH
-
Dresden, Germany, 01307
- Carl Gustav Carus University Hospital, Department of Dermatology
-
Gera, Germany, 07548
- SRH Wald-Klinikum Gera, Center for Clinical Studies
-
Hannover, Germany, 30625
- Hannover Medical School, Department for Dermatology, Allergy and Venereology
-
Leipzig, Germany, 04103
- SIBAmed Studienzentrum GmbH & Co KG
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Atopic dermatitis (intrinsic disease without IgE mediated sensitization defined by negative history and negative SX-1 CAP FEIA or extrinsic disease defined by positive history and / or positive SX-1 CAP FEIA),
- SCORAD index score ≥ 25,
- EASI ≥ 16,
- Male and female patients at the age of 18 to 85 years,
- Signed Informed Consent,
- Subjects must be able to understand and communicate with the investigator and comply with the requirements of the study and must give a written, signed and dated informed consent before any study related activity is performed,
- Subject is judged to be in good general health as determined by the principal investigator based upon the results of medical history, laboratory profile, and physical examination,
- Patients with stable chronic asthma, treated with inhaled corticosteroids, will be allowed to participate.
Exclusion Criteria:
- Other inflammatory skin disease than atopic dermatitis,
- Use of cyclosporine, azathioprine, mycophenolate [wash-out period of 4 weeks]; Phototherapy (PUVA, NB-UVB, UVA1; [wash-out period of 2 weeks]), Dupilumab (Dupixent®; [wash-out period of 12 weeks])
- Subjects expected to be exposed to an undue safety risk if participating in the trial including chronic infections,
- Contraindications of Secukinumab by label (i.e. approval for the treatment of psoriasis in the EU - refer to point 14 - 16 at the bottom of this section),
- Current severe progressive or uncontrolled disease which in the judgment of the investigator renders the subject unsuitable for the trial,
- Plans for administration of live vaccines during the study period,
- Chronic infection,
- Patients with instable chronic asthma,
- Any chronic inflammatory bowel disease (e.g. Crohn's disease),
- Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive hCG laboratory test (>10 mIU/mL),
Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant, unwilling to use effective contraception during the study and for 20 weeks after stopping treatment. Effective contraception is defined as either:
Barrier method: Condom or occlusive cap (diaphragm or cervical/vault caps) with spermicide (where available). Spermicides alone are not a barrier method of contraception and should not be used alone,
The following methods are considered more effective than the barrier method and are also acceptable:
- Total abstinence: When this is in line with the preferred and usual lifestyle of the subject (Periodic abstinence [e.g. calendar, ovulation, symptothermal, post-ovulation methods] and withdrawal are not acceptable methods of contraception),
- Female sterilization: have had a surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment,
- Male partner sterilization (at least 6 months prior to screening). For female subjects on the study, the vasectomized male partner should be the sole partner for that subject,
- Use of established oral, injected or implanted hormonal methods of contraception, intrauterine device (IUD) or intrauterine system (IUS) NOTE: Women are considered post-menopausal and not of child bearing potential if they have had:
i. 12 months of natural (spontaneous) amenorrhea with an appropriate clinical profile (e.g. age appropriate, history of vasomotor symptoms) or • six months of spontaneous amenorrhea with serum FSH levels >40 mIU/mL
Or
ii. Surgical bilateral oophorectomy (with or without hysterectomy) or tubal ligation at least six weeks before taking study treatment. In case of oophorectomy alone, only when the reproductive status of the woman has been confirmed by follow up hormone level assessment is she considered not of child bearing potential.
- History of human immunodeficiency virus (HIV) infection or positive HIV serology at screening,
- Positive with hepatitis B surface antigen (HBsAg) or hepatitis C antibody at the screening visit (a report ≤ 6 months is also accepted),
- History of alcohol or drug abuse within 1 year of the screening visit,
- Planned major surgical procedure during the patient's participation in this study,
- Hypersensitivity against Secukinumab,
- Active or reactive tuberculosis,
- Participation in other clinical studies.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment Arm A
Patients in treatment arm A receive 300 mg Secukinumab administered as 2 subcutaneous injections of 150 mg (i.e.
2x 150 mg) at baseline day 1 and week 1, 2, 3, 4, 8, 12 and injections with placebo at week 5, 6, 7 and 16.
For assessments of the study endpoints were followed up visits at week 20 and 24.
Placebo will be administered as 2 subcutaneous injections.
|
Solution for injection in pre-filled syringe
Other Names:
Solution for injection in pre-filled syringe
Other Names:
|
Placebo Comparator: Treatment Arm B
Patients in treatment arm B receive placebo until visit 3 (week 3) and will switch to Secukinumab 300 mg s.c. up from visit 4 (week 4), visit 5, 6, 7, 8, 12 and16.
For assessments of the study endpoints were followed up visits at week 20 and 24.
|
Solution for injection in pre-filled syringe
Other Names:
Solution for injection in pre-filled syringe
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in EASI
Time Frame: week 4 (visit 4)
|
Proportion of patients with a reduction of the eczema score EASI of at least 50%.
The proportions are then compared between study arms.
|
week 4 (visit 4)
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction of EASI
Time Frame: baseline (day 1, visit 0) and End of Trial (Arm A week 12 / Arm B week 16)
|
To compare the proportions of patients with a reduction of the eczema score EASI 50.
|
baseline (day 1, visit 0) and End of Trial (Arm A week 12 / Arm B week 16)
|
Reduction of EASI
Time Frame: Arm A week 12 / Arm B week 16
|
To compare the number of patients with a reduction of the eczema score EASI 50.
|
Arm A week 12 / Arm B week 16
|
Reduction in SCORAD (Scoring atopic dermatitis)
Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16
|
The number of patients with a reduction of 50 % in SCORAD index.
|
day 1, week 4 and Arm A week 12 / Arm B week 16
|
Change in pruritus score (Visual Analogue Scale)
Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16
|
To compare the proportion of patients with change in pruritus score (VAS) by 50 %.
|
day 1, week 4 and Arm A week 12 / Arm B week 16
|
Change in IGA Score (5-point Investigator's Global Assessment)
Time Frame: Arm A week 12 / Arm B week 16
|
To compare the proportion of patients who achieve a score of "clear-0" or "almost clear-1" in the static IGA score compared to baseline.
|
Arm A week 12 / Arm B week 16
|
Serum biomarkers CCL17 and CCL22
Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16
|
To compare the serum biomarkers CCL17 and CCL22.
|
day 1, week 4 and Arm A week 12 / Arm B week 16
|
Increase in DLQI (Dermatology Life Quality Index)
Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16
|
To compare the proportion of patients achieving increase in DLQI by 30 %.
|
day 1, week 4 and Arm A week 12 / Arm B week 16
|
Consumption of topical methylprednisolone aceponate
Time Frame: day 1, week 4 and Arm A week 12 / Arm B week 16
|
To evaluate the quantification of the consumption of topical methylprednisolone aceponate 0.1% in gram.
|
day 1, week 4 and Arm A week 12 / Arm B week 16
|
Serious and non-serious adverse drug reactions
Time Frame: treatment phase (day 1 up to week 16), follow-up phase (week 20, week 24)
|
To observe any serious adverse drug reactions and non-serious adverse drug reactions.
|
treatment phase (day 1 up to week 16), follow-up phase (week 20, week 24)
|
Gender distribution in patients with atopic dermatitis
Time Frame: study arm A week 4 and both study arms week 16
|
Subgroup analyses will be performed to compare the effects of treatment with Secukinumab in male and female patients.
Therefore, the recorded gender data will be used and separately analyzed for the above mentioned primary and secondary endpoints.
|
study arm A week 4 and both study arms week 16
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Stefan Beissert, Prof. Dr.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Secu_Trial
- 2016-005181-57 (EudraCT Number)
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dermatitis, Atopic
-
Catalysis SLCompletedAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related Conditions | Atopic Dermatitis \(AD\)Serbia
-
Jacob Pontoppidan ThyssenThe Novo Nordic FoundationRecruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis FlareDenmark
-
ShaperonNot yet recruitingAtopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis of Scalp
-
University of California, San FranciscoSanofi; Regeneron PharmaceuticalsRecruitingEczema | Atopic Dermatitis | Atopic Dermatitis Eczema | Atopic Dermatitis and Related ConditionsUnited States
-
PfizerActive, not recruitingEczema | Atopic Dermatitis | Eczema, Atopic | Atopic Dermatitis, UnspecifiedUnited States, Canada, Czechia, Poland
-
AmgenCompletedDermatitis, Atopic DermatitisCanada, United States, Japan
-
Hadassah Medical OrganizationUnknownATOPIC DERMATITIS
-
SanofiCompletedAtopic Dermatitis | Dermatitis AtopicChina
-
SanofiCompletedDermatitis AtopicSaudi Arabia, Kuwait, United Arab Emirates
-
National Institute of Allergy and Infectious Diseases...Atopic Dermatitis Research NetworkCompletedAtopic Dermatitis (AD) | Non-atopic Healthy ControlsUnited States
Clinical Trials on Secukinumab 300 mg
-
Novartis PharmaceuticalsWithdrawn
-
Novartis PharmaceuticalsCompletedChronic Plaque PsoriasisUnited States
-
Novartis PharmaceuticalsCompletedModerate to Severe Chronic Plaque-Type PsoriasisUnited States, Germany, Japan, Bulgaria, Czechia, Singapore, Switzerland, United Kingdom, Italy, France, Vietnam, Poland, Slovakia, Austria, Canada
-
Novartis PharmaceuticalsCompletedPsoriatic ArthritisUnited Kingdom, Germany, Italy, Spain, United States, Australia, Bulgaria, Russian Federation, Czechia, Canada, Netherlands, Switzerland, Puerto Rico
-
Novartis PharmaceuticalsCompletedLichen Planus: Cutaneous Lichen Planus, Mucosal Lichen Planus and Lichen PlanopilarisGermany, United States, France
-
Novartis PharmaceuticalsCompletedModerate to Severe Palmoplantar PsoriasisBelgium, United States, Hungary, Russian Federation, Turkey, Australia, Israel, Netherlands, Portugal, Spain, United Kingdom, Norway, Slovakia, Canada, Finland
-
Novartis PharmaceuticalsCompletedChronic Scalp PsoriasisUnited States
-
Novartis PharmaceuticalsCompleted
-
Novartis PharmaceuticalsCompletedModerate to Severe Plaque-type PsoriasisGermany, United States, Estonia, France, Canada
-
Novartis PharmaceuticalsCompletedPlaque PsoriasisChina, Thailand, Philippines, Turkey, Hungary, Malaysia